Skip to main content

Turn Therapeutics Inc. (TTRX)

Sector
Healthcare
Industry
Biotechnology
Last price
$8.55
As of

Kresmion compiles this page from TTRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Turn Therapeutics Inc. (TTRX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-10.

As of . Source: SEC EDGAR filings for TTRX. Method and limitations.

COMPANY DOSSIER

See the full TTRX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TTRX on one page. Preview it with sample data, then open it live with a free account.

Preview the TTRX dossier

Active events for TTRX

  • mediumEarnings below estimates

    Q3-2026: Missed consensus by 137.6%, EPS $-0.21 vs $-0.0884 estimate

  • lowEarnings above estimates

    Q4-2025: EPS $0.01 vs $-0.0408 estimate, +0.05 on a near-zero consensus

FREE, NO ACCOUNT

Every event on TTRX, as it fires

New filings, 13F moves and cross asset events on TTRX land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, TTRX

Going concern statement

TTRX's 10-Q filed Nov 9, 2026 states:

…which raises substantial doubt about our ability to continue as a going concern.

Read the 10-Q on SEC EDGAR Every company with a going concern statement

More data on TTRX

TTRX against its peers

TTRX's return on equity of -68.2% ranks in the 38th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.

MetricTTRXPeer medianPercentilen
Revenue FYn/a23.6Mn/a14
Operating marginn/a-303.2%n/a12
Net marginn/a-303.5%n/a12
Return on equity-68.2%-46.0%3816
1 year215.5%-27.3%9320

Peers (20): EVMN, NAUT, EBS, DTIL, IPSC, AGEN, OCGN, GALT, ALLO, AUTL, KYTX, CABA, LRMR, PRLD, BNTC, NWBO, XFOR, ENTA, ALT, SABS. Left out: AGMB (no annual filing), SCTX (no annual filing), VOGX (no annual filing), VCRE (no annual filing), EIKN (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TTRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in TTRX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TTRX in the last 180 days.

Upstream: SEC EDGAR filings for TTRX

Kresmion, "Turn Therapeutics Inc. (TTRX) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/TTRX. Upstream data: SEC EDGAR filings for TTRX.

Link to this data (HTML):

<a href="https://kresmion.com/research/TTRX">Turn Therapeutics Inc. (TTRX) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow TTRX on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TTRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the TTRX dossier
Share

The TTRX intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.